pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Kite Pharma Inc

updated 3mo ago
Website ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
KITE-363
Diffuse Large B-Cell Lymphoma

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Kite Pharma Inc jobs →

News

  • Milestone cutting 20% of HQ team, including CMO
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 20h ago
  • Cellectis will shed 70% of workforce as part of in vivo pivot
    Cellectis’ pivot from allogeneic CAR-Ts to in vivo therapies is set to come at the expense of 70% of its workforce.
    fiercebiotech · 1d ago
  • Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials
    Gilead Sciences announced on its third-quarter earnings call Oct. 29 that the company has placed a partial clinical hold on two studies for the CAR-T cell therapy KITE-753 in diffuse large B-cell l…
    fiercebiotech · 15d ago
  • Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs
    Parkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are each hoping to raise around $134 million from their respective IPOs.
    fiercebiotech · 18d ago
  • Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOs
    Parkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug developers to eye up a public listing.
    fiercebiotech · 1mo ago
  • CAR-T biotech Caribou makes ‘heartbreaking’ call to shrink headcount, halt pipeline
    The Bay Area biotech is discontinuing all clinical development activities and implementing a "substantial reduction in workforce."
    fiercebiotech · 1mo ago
  • BioSpace 40 Under 40 winners make their mark on biopharma
    40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million up-fron…
    biospace · 1mo ago
  • Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
    Cellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.
    fiercebiotech · 2mo ago
  • CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
    Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammati…
    fiercebiotech · 2mo ago
  • ArsenalBio sheds most of staff in pivot to in vivo CAR-T
    About a year after halving its staff in a clinical push, Arsenal Biosciences is now making a hard pivot that involves laying off most of its employees and seeking out new homes for its assets.
    fiercebiotech · 2mo ago
view all news mentions →
identifiers
source
globaldata
top tags
DLBCL1Oncology1
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?